Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Qwo for Mild to Moderate Cellulite in Adult Females
NCT05026216Phase 4Completed
- Sponsor
- DMR Clinical Research
- Start
- Mar 2021
- Primary completion
- Aug 2021
- Modality
- Therapeutic Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of collagenase clostridium histolyticum in cellulite, sponsored by DMR Clinical Research. Primary endpoints: Proportion of Subjects With >=1-point Improvement on Investigator Global Aesthetic Improvement Scale (I-GAIS) at Day 90 (Buttocks) and Number of Participants With >=1-Point Improvement on Investigator Global Aesthetic Improvement Scale (I-GAIS) at Day 90 (Thighs). Started Mar 2021; status: completed.
02
Drugs
collagenase clostridium histolyticum
03
Conditions
cellulite
Beyond the preview
Go deeper on NCT05026216.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05026216.